文献速递中毒与环境急症复苏、休克与脓毒症呼吸衰竭与机械通气

大鼠中赛拉嗪与芬太尼过量的呼吸及心脏毒性

Respiratory and cardiac toxicity of xylazine and fentanyl overdose in rats.
PubMed 文献 · Clin Toxicol (Phila) · 2026-01-20
一句话结论大鼠模型中赛拉嗪剂量依赖性地增强芬太尼所致呼吸抑制和心血管崩溃,10 mg/kg 联合芬太尼在2-3分钟内致无脉电活动且100%死亡。

研究在成年Sprague-Dawley大鼠中经静脉给予赛拉嗪单用或联合芬太尼(150 μg/kg),赛拉嗪设0.1、1、10 mg/kg三个剂量,用开放气流体积描记法测通气与肺气体交换、遥测与超声心动图评估心血管功能。结果:0.1 mg/kg赛拉嗪联合芬太尼死亡率无增加(12.5% vs 芬太尼单用10.5%),但延长呼吸暂停;1 mg/kg使芬太尼死亡率升至62.5%,存活者呼吸逐步恢复、非存活者因呼吸衰竭继发心源性休克;10 mg/kg联合芬太尼100%致死,2-3分钟内快速心源性休克导致无脉电活动。结论:赛拉嗪剂量依赖性地增强芬太尼所致呼吸抑制与心血管崩溃。

要点

  • 大鼠中赛拉嗪10 mg/kg联合芬太尼(150 μg/kg)100%致死,2-3分钟内快速心源性休克进展为无脉电活动。
  • 赛拉嗪1 mg/kg联合芬太尼死亡率62.5%,非存活者因呼吸衰竭继发心源性休克,存活者呼吸逐步恢复。
  • 赛拉嗪0.1 mg/kg联合芬太尼死亡率12.5%,芬太尼单用10.5%,死亡率无增加但呼吸暂停延长。
  • 赛拉嗪0.1 mg/kg联合芬太尼降低芬太尼所致呼吸肌僵直与氧耗。
  • 赛拉嗪单用0.1 mg/kg呈典型α2肾上腺素能激动剂表现,10 mg/kg转为显著持续高血压。

适用人群与场景

  • 成年雄性及雌性Sprague-Dawley大鼠,经静脉给予赛拉嗪单用或联合芬太尼150 μg/kg。
  • 赛拉嗪剂量选择0.1 mg/kg、1 mg/kg、10 mg/kg,与报告的人体暴露一致。

处置流程与药物剂量

  • 赛拉嗪0.1 mg/kg、1 mg/kg或10 mg/kg单用或联合芬太尼150 μg/kg,经静脉推注给药。

红旗征与不能漏的情况

  • 赛拉嗪10 mg/kg联合芬太尼可在2-3分钟内出现快速心源性休克并进展为无脉电活动,100%致死。
  • 赛拉嗪1 mg/kg联合芬太尼时非存活者出现呼吸衰竭继发心源性休克。

研究设计与关键结果

  • 研究类型:大鼠实验研究;成年雄雌Sprague-Dawley大鼠经静脉给予赛拉嗪单用或联合芬太尼150 μg/kg,赛拉嗪剂量0.1、1、10 mg/kg;用开放气流体积描记法测通气与肺气体交换,遥测与超声心动图评估心血管功能。
  • 赛拉嗪0.1 mg/kg联合芬太尼死亡率12.5%,芬太尼单用死亡率10.5%,死亡率无增加,但呼吸暂停延长。
  • 赛拉嗪0.1 mg/kg联合芬太尼降低芬太尼所致呼吸肌僵直与氧耗。
  • 赛拉嗪1 mg/kg联合芬太尼死亡率62.5%,存活者呼吸逐步恢复,非存活者出现呼吸衰竭继发的心源性休克。
  • 赛拉嗪10 mg/kg联合芬太尼死亡率100%,2-3分钟内快速心源性休克导致无脉电活动。
  • 赛拉嗪单用0.1 mg/kg呈典型α2肾上腺素能激动剂表现,10 mg/kg出现显著持续高血压。

证据类型、等级与局限

  • 证据类型:动物实验(大鼠)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Xylazine, a veterinary sedative, is an adulterant increasingly found in illicit fentanyl supplies. Yet, the dose-dependent effects of xylazine on fentanyl overdose remain poorly characterized. We sought to determine how xylazine modifies fentanyl-induced mortality, respiratory depression, and cardiovascular dysfunction in rats.

METHODS: Adult male and female Sprague-Dawley rats received non-lethal xylazine alone or combined with fentanyl (150 μg/kg) intravenously. For xylazine, three doses (0.1 mg/kg, 1 mg/kg, or 10 mg/kg) were chosen that produced a dose-dependent transition from a predominantly α2-adrenergic receptor agonist to a non-specific α-adrenergic receptor agonist effect, and are consistent with reported human exposures. Ventilation and pulmonary gas exchange were measured using an open-flow plethysmograph. Cardiovascular function was assessed via telemetry and echocardiography.

RESULTS: Bolus injection of xylazine alone at 0.1 mg/kg produced a typical profile of an α2-adrenergic agonist transitioning to a pronounced and persistent hypertension at 10 mg/kg. Xylazine dose-dependently potentiated the toxicity of fentanyl. Xylazine at 0.1 mg/kg with fentanyl showed no mortality increase (12.5% versus 10.5% fentanyl alone) despite prolonging apnea. Of note, this dose reduced fentanyl-induced rigidity of respiratory muscles and oxygen consumption. Xylazine at 1 mg/kg dramatically increased fentanyl mortality (62.5%), with survivors showing progressive respiratory recovery while non-survivors developed cardiogenic shock secondary to respiratory failure. Xylazine at 10 mg/kg with fentanyl was universally fatal (100%), causing a unique clinical syndrome, consisting of rapid cardiogenic shock leading to a pulseless electrical activity within 2-3 min.

DISCUSSION: Xylazine, when combined with a fentanyl overdose, has no increased mortality at 0.1 mg/kg, exacerbates hypoxemia-driven toxicity on breathing generation and cardiac function at 1 mg/kg, while producing an acute and very rapid lethal cardiocirculatory failure at 10 mg/kg.

CONCLUSION: Xylazine significantly potentiates fentanyl-induced respiratory depression and cardiovascular collapse in a dose-dependent manner in rats.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Lewis T, Judenherc-Haouzi A, Reinhardt A, et al. Respiratory and cardiac toxicity of xylazine and fentanyl overdose in rats. Clin Toxicol (Phila). 2026. PMID: 41557468. doi:10.1080/15563650.2025.2598328

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。